Cite
MLA Citation
J. Zhang et al.. “148P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC).” Immuno-oncology technology, vol. 16, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100172206555.0x00000e